Save on Sodium Zirconium Cyclosilicate with Coupons, Discounts & Savings Programs

Sodium Zirconium Cyclosilicate is available as 5 g and 10 g packet for oral suspension.

Sodium Zirconium Cyclosilicate is a potassium binder that is used for the treatment of high potassium levels (hyperkalemia) in adults.

Sodium Zirconium Cyclosilicate is a potassium binder. It works by binding (attaching) to potassium in your stomach and intestines (gut) so that your body can’t absorb it. It’s then passed through your stool, which lowers the levels of potassium in your blood.

Your dose of Sodium Zirconium Cyclosilicate is based on how your potassium level is responding to the medication and if you’re getting side effects.

In general:

• Adults: The typical starting dose is 10 grams mixed with at least 3 tablespoons of water and taken by mouth three times per day, for up to 2 days. The typical maintenance dose ranges from 5 grams every other day to 15 grams daily
• Adults on long-term dialysis: The typical starting dose is 5 to 10 grams mixed with at least 3 tablespoons of water and taken by mouth once per day on non-dialysis days only. The typical maintenance dose rangers from 5 grams to 15 grams once per day on non-dialysis days only

Sodium Zirconium Cyclosilicate is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Sodium Zirconium Cyclosilicate:

• Swelling in the hands, legs, and feet

Serious side effects are rare with Sodium Zirconium Cyclosilicate.

The following medications may interact with Sodium Zirconium Cyclosilicate:

• In general, other oral medications should be administered at least 2 hours before or 2 hours after Sodium Zirconium Cyclosilicate

Various FDA-approved generic manufacturers

Sodium Zirconium Cyclosilicate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug.

• Lokelma